Wagner O F, Vierhapper H, Gasic S, Nowotny P, Waldhäusl W
I. Medical Department, University of Vienna, Austria.
Eur J Clin Invest. 1992 Apr;22(4):277-82. doi: 10.1111/j.1365-2362.1992.tb01463.x.
To determine the impact of i.v. endothelin-1 on systemic, pulmonary and splanchnic circulation, as well as the peptide's regional clearance, hepatic venous and right heart catheterization was performed in healthy volunteers. During the peptide's continuous i.v. administration (0.4 pmol x kg-1 x min-1, 60 min) its plasma concentration rose from 2.1 +/- 0.5 to 9.5 +/- 5.3 pmol/l (pulmonary artery), from 2.1 +/- 0.9 to 5.0 +/- 1.6 pmol/l (femoral artery), and from 1.5 +/- 0.6 to 2.9 +/- 1.2 pmol/l (hepatic vein). This was accompanied by an increase in mean systolic arterial pressure from 127 +/- 14 to 131 +/- 12 mmHg (P less than 0.05). Concomitantly, cardiac output and heart rate decreased from 7.0 +/- 1.1 to 5.8 +/- 1.0 l/min and from 63 +/- 6 to 56 +/- 5 beats/min, respectively, while total vascular resistance increased from 964 +/- 273 to 1204 +/- 338 dyn x cm x s-5 (P less than 0.01). No major changes in pulmonary circulation were observed, while splanchnic vascular resistance increased from 4472 +/- 1056 to 5361 +/- 1420 dyn x cm x s-5 (P less than 0.01) and estimated hepatic blood flow decreased from 1403 +/- 218 to 1218 +/- 219 ml min-1 (P less than 0.01). During endothelin-1 infusion the pulmonary vascular bed accounted for approximately 53% of the peptide's overall disposal.(ABSTRACT TRUNCATED AT 250 WORDS)
为确定静脉注射内皮素-1对体循环、肺循环和内脏循环的影响以及该肽的局部清除情况,对健康志愿者进行了肝静脉和右心导管插入术。在持续静脉输注该肽(0.4 pmol·kg⁻¹·min⁻¹,60分钟)期间,其血浆浓度在肺动脉处从2.1±0.5升至9.5±5.3 pmol/L,在股动脉处从2.1±0.9升至5.0±1.6 pmol/L,在肝静脉处从1.5±0.6升至2.9±1.2 pmol/L。同时,平均收缩压从127±14 mmHg升至131±12 mmHg(P<0.05)。相应地,心输出量和心率分别从7.0±1.1降至5.8±1.0 L/min和从63±6降至56±5次/分钟,而总血管阻力从964±273增至1204±338 dyn·cm·s⁻⁵(P<0.01)。未观察到肺循环有重大变化,而内脏血管阻力从4472±1056增至5361±1420 dyn·cm·s⁻⁵(P<0.01),估计肝血流量从1403±218降至1218±219 ml·min⁻¹(P<0.01)。在内皮素-1输注期间,肺血管床约占该肽总清除量的53%。(摘要截短于250字)